Literature DB >> 9803086

Loss to follow-up of patients with abnormal Pap smear: magnitude and reasons.

J Thinkhamrop1, P Lumbiganon, S Jitpakdeebodin.   

Abstract

We studied the magnitude and reasons for loss to follow-up in cases of abnormal Pap smears. We studied 162 women whose Pap smear results were abnormal. The lost follow-up rate was 41.1 per cent (95% CI: 33.1 to 49.3). Reasons for not coming to receive treatment was mostly related to communication such as not receiving informed letters from the hospital (35.6%), not understanding the messages in the informed letters (10.2%), were informed from the hospital's letters that their results were normal (5.1%), and perceiving that the test result was not serious (13.6%). One third of them had traveling-related reasons. There were 25.4 per cent of patients who sought treatment at other hospitals and 8.5 per cent went to see a traditional healer for treatment. The results provide information to prevent such unnecessary loss after having a Pap smear screening test for cervical carcinoma.

Entities:  

Mesh:

Year:  1998        PMID: 9803086

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  3 in total

1.  The costs of reducing loss to follow-up in South African cervical cancer screening.

Authors:  Jeremy D Goldhaber-Fiebert; Lynette E Denny; Michelle De Souza; Thomas C Wright; Louise Kuhn; Sue J Goldie
Journal:  Cost Eff Resour Alloc       Date:  2005-11-15

2.  Evaluating a community-based cervical cancer screening strategy in Western Kenya: a descriptive study.

Authors:  Megan Swanson; Saduma Ibrahim; Cinthia Blat; Sandra Oketch; Easter Olwanda; May Maloba; Megan J Huchko
Journal:  BMC Womens Health       Date:  2018-07-03       Impact factor: 2.809

3.  A public health approach to cervical cancer screening in Africa through community-based self-administered HPV testing and mobile treatment provision.

Authors:  Miriam Nakalembe; Philippa Makanga; Andrew Kambugu; Miriam Laker-Oketta; Megan J Huchko; Jeffrey Martin
Journal:  Cancer Med       Date:  2020-09-23       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.